Colica Carmela, Di Renzo Laura, Trombetta Domenico, Smeriglio Antonella, Bernardini Sergio, Cioccoloni Giorgia, Costa de Miranda Renata, Gualtieri Paola, Sinibaldi Salimei Paola, De Lorenzo Antonino
CNR, IBFM UOS of Germaneto, University "Magna Graecia" of Catanzaro, Campus "Salvatore Venuta", 88100 Germaneto, Catanzaro, Italy.
Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Oxid Med Cell Longev. 2017;2017:2473495. doi: 10.1155/2017/2473495. Epub 2017 Aug 9.
Hydroxytyrosol (HT) plays a significant role in cardiovascular disease (CVD) protection, and its metabolites are able to protect from the endothelial dysfunction commonly present in atherosclerosis. This randomized double-blinded, placebo-controlled crossover trial determined the effect in healthy volunteers of two gastroresistant capsules containing 15 mg/day of HT, for a 3-week period (HTT). Evaluation of nutritional status, serum metabolites, oxidative stress biomarkers, and gene expression of 9 genes related to oxidative stress, inflammation, and CVDs was performed. Oxidation biomarkers like thiol group ( = 0.001), total antioxidant status (TAS) ( = 0.001), superoxide dismutase 1 (SOD1) (2 = 3.7), and plasma concentration of HT (2.83 g·mL) were significantly increased, while nitrite ( = 0.001), nitrate ( = 0.001), and malondialdehyde (MDA) ( = 0.02) were drastically reduced after HTT. A significant reduction of body fat mass percentage ( = 0.01), suprailiac skinfold ( = 0.01), and weight ( = 0.04; Δ% = -0.46%) was observed after HTT. This study shows that regular intake of 15 mg/day of HT changed body composition parameters and modulated the antioxidant profile and the expression of inflammation and oxidative stress-related genes. However, it is advisable to personalize HT doses in order to exert its health benefits in CVD prevention and protection of LDL-C particles from oxidative damage. This trial is registered with ClinicalTrials.gov NCT01890070.
羟基酪醇（HT）在心血管疾病（CVD）防护中发挥着重要作用，其代谢产物能够预防动脉粥样硬化中常见的内皮功能障碍。这项随机双盲、安慰剂对照的交叉试验确定了含15毫克/天HT的两种胃溶胶囊在3周内（HTT）对健康志愿者的影响。对营养状况、血清代谢产物、氧化应激生物标志物以及与氧化应激、炎症和心血管疾病相关的9个基因的基因表达进行了评估。HTT后，硫醇基团（=0.001）、总抗氧化状态（TAS）（=0.001）、超氧化物歧化酶1（SOD1）（2=3.7）等氧化生物标志物以及HT的血浆浓度（2.83微克·毫升）显著增加，而亚硝酸盐（=0.001）、硝酸盐（=0.001）和丙二醛（MDA）（=0.02）则大幅降低。HTT后，体脂质量百分比（=0.01）、髂上皮肤褶厚度（=0.01）和体重（=0.04；Δ%=-0.46%）显著降低。本研究表明，每天规律摄入15毫克HT可改变身体成分参数，调节抗氧化谱以及炎症和氧化应激相关基因的表达。然而，为了在预防心血管疾病和保护低密度脂蛋白胆固醇（LDL-C）颗粒免受氧化损伤方面发挥其健康益处，建议对HT剂量进行个性化调整。该试验已在ClinicalTrials.gov注册，注册号为NCT01890070。
